-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Adrixetinib in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Adrixetinib in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Adrixetinib in Non-Small Cell Lung Cancer Drug Details: Adrixetinib (Q-702)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Adrixetinib in Hematological Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Adrixetinib in Hematological Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Adrixetinib in Hematological Tumor Drug Details: Adrixetinib (Q-702) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KITE-718 in Primary Mediastinal B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - KITE-718 in Primary Mediastinal B-Cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. KITE-718 in Primary Mediastinal B-Cell Lymphoma Drug Details: KITE-718...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – (Cisplatin + Vinblastine Sulphate) in Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Cisplatin + Vinblastine Sulphate) in Ovarian Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Cisplatin + Vinblastine Sulphate) in Ovarian Cancer Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Aglatimagene Besadenovec in High-Grade Glioma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Aglatimagene Besadenovec in High-Grade Glioma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Aglatimagene Besadenovec in High-Grade Glioma Drug Details: aglatimagene besadenovec is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Zilovertamab Vedotin in Ureter Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Zilovertamab Vedotin in Ureter Cancer Drug Details: Zilovertamab vedotin is under development for the treatment...
-
Product Insights
Pulmonary Tuberculosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Pulmonary Tuberculosis - Drugs In Development, 2023’, provides an overview of the Pulmonary Tuberculosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Pulmonary Tuberculosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...